Molecular Characterization of G6PD Deficiency at a North Indian Centre: Implications for Diagnostic Testing Laboratories in Different Regions of India

Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic

“…For category 0–1 in newly diagnosed CML in chronic phase (CML-CP), one should go ahead with planned therapy, while ongoing treatment need not be changed for CML-CP. [ 5 ]. For category 2–3, we should weigh the risks and benefits of starting Imatinib.…”

“…However delay in AML induction or administration of suboptimal induction can adversely impact the treatment outcomes. Hence for Category 0–1, one should investigate and treat normally as per institutional guidelines [ 5 ]. For category 2–3, it is advisable to wait for 2–3 weeks [ 9 ].…”

“…Consolidation with allogeneic hematopoietic cell transplantation may be limited at many institutions during ongoing pandemic. For relapsed and/or refractory AML, salvage treatment with Azacitidine and Venetoclax with frequent day-care visits is an acceptable option for patients who are unable to get inpatient admission [ 5 ].…”

“…For newly diagnosed Paediatric/Adult ALL one may continue as per institutional practice in category 0–1, while wait until recovery is advised in category 2–3 [ 5 , 14 , 15 ]. Corticosteroids are generally part of standard treatment of COVID-19 infection and hence they can be continued in any category.…”

“…It is preferable to give subcutaneous bortezomib at home. We can use zoledronic Infusion monthly for 1st six months then change to every 3 months [ 5 ]. Denosumab can be considered, if affordable, instead of zoledronic acid, as it can be administered subcutaneous at home.…”